Archive: Company News
1STBIO and LigaChemBio Announce Strategic R&D and Licensing Option Agreement
— Expanded collaboration leverages complementary expertise to unlock next-generation oncology therapeutics
— Focus on breakthrough ADC payloads and immuno-oncology candidates with out-licensing potential
YONGIN, South Korea, April 22, 2025 — 1ST Biotherapeutics, Inc. (“1STBIO”) and LigaChem Biosciences(KOSDAQ: 141080KS, “LigaChemBio”) announced that they have entered into a strategic partnership and licensing option agreement to co-develop novel payloads for antibody-drug conjugates (ADCs) as well as small molecule immuno-oncology therapies. Read more…
Four new members elected to the Board of Directors of MetrioPharm AG
— Their appointment was initiated by the outgoing board of directors. The four new members will bring many years of experience in the biotech and pharmaceutical industry, especially in research and development, pharmaceutical strategy and regulatory affairs.
MetrioPharm AG, a biotech company developing drugs for inflammatory and infectious diseases, announced today that four new members were elected to the Board of Directors at an Extraordinary General Meeting on April 25, 2025. The new members are Dr. Harald Fricke, Dr. Martina Muttke, Dr. Stephan Rietiker and Dr. Jörg Zwicker. The board members Jörg Gruber and Christoph von Moos will be remaining on the board.
1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research
— Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options
1ST Biotherapeutics, Inc. (1STBIO), a clinical-stage biopharmaceutical company focused on advancing therapies for neurodegenerative diseases and cancer, today announced its participation in The Michael J. Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program. As an industry partner in this initiative, 1STBIO will bring innovative approaches to LRRK2 research and accelerate the development of new therapies for Parkinson’s patients.
Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development
— First-ever use of Ebenbuild’s Twinhale technology in idiopathic pulmonary fibrosis lung models
— Trial results published in Nature Communications
Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced its contribution to a pioneering study published today in Nature Communications. The article titled Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment(DOI:10.1038/s41467-025-58568-x) highlights the potential of inhaled therapeutics for treating idiopathic pulmonary fibrosis (IPF), a devastating lung disease with limited treatment options. Read more…